Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer

1 May 2015

Abstract excerpt

Our understanding of the genetic and nongenetic molecular alterations associated with anti-epidermal growth factor receptor (EGFR) therapy resistance in colorectal cancer (CRC) has markedly expanded in recent years. Mutations in RAS genes (KRAS/NRAS exons 2, 3, or 4) predict a lack of clinical benefit when anti-EGFR monoclonal antibodies (mAbs) are added to chemotherapy. Genetic events in additional nodes of the...

Topics

Join the communities discussing this publication.

Colorectal Cancer Treatments and Studies
Gastric Cancer Management and Outcomes
Hepatocellular Carcinoma Treatment and Prognosis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25993166
DOI: 10.14694/edbook_am.2015.35.e149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerPMID 25993166Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Semantic proximity Read ↗

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.Semantic proximity Read ↗

Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Semantic proximity Read ↗

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.Semantic proximity Read ↗

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read ↗

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.